Gene therapy injection takes on advanced cancers in first human trial
NCT ID NCT07207681
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 20 times
Summary
This early-phase study tests a new gene therapy injection called KXV01 TCR Lentinvivo in 30 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will monitor side effects and look for signs that the therapy is shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Hospital of Jilin University
Changchun, Jilin, 130013, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.